Genmab A/S (GMAB) Institutional Ownership

Ownership Summary

A total of 247 institutions have reported a stake in Genmab A/S (NASDAQ:GMAB) as of September 2025, according to recent 13F filings with the SEC.

• These investors collectively held 96.2% of the company's total shares outstanding in September 2025, up from 90.6% in June 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by -5.11%, with a year-over-year an increase of 11.26% in the count of filers.
• During the quarter, 141 institutions bought more Genmab A shares, 82 sold shares, and 24 of the 247 total investors held their position steady.
• The aggregate institutional position in Genmab A now stands at 61.74Mn shares as of September 2025, after investors decreased their holdings (down by 3.32Mn shares quarter on quarter which is up 10.22Mn shares year over year).
• As of September 30, 2025, Orbis Allan Gray Ltd held Genmab A's largest shareholding position with over 11.08Mn shares, representing 17.27% of total outstanding shares.
• Among the most significant buyers of Genmab A during September 2025 were Paradigm Biocapital Advisors LP (3.82Mn), Orbis Allan Gray Ltd (3.16Mn), HARDING LOEVNER LP (561.05K), FMR LLC (439.18K), FEDERATED HERMES, INC. (418.25K).
• Leading sellers of Genmab A stock in September 2025 included CITADEL ADVISORS LLC (4.38Mn), Deep Track Capital, LP (1.52Mn), MARSHALL WACE, LLP (1.37Mn), MORGAN STANLEY (1.02Mn), VOLORIDGE INVESTMENT MANAGEMENT, LLC (818.36K).
• The top 10 institutional holders of Genmab A for the quarter ending September 2025 included Orbis Allan Gray Ltd (11.08Mn), ALLIANCEBERNSTEIN L.P. (10.95Mn), Paradigm Biocapital Advisors LP (3.82Mn), ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (3.64Mn), HARDING LOEVNER LP (3.48Mn), BlackRock, Inc. (3.45Mn), RENAISSANCE TECHNOLOGIES LLC (2.82Mn), FIRST TRUST ADVISORS LP (1.69Mn), MORGAN STANLEY (1.67Mn), TWO SIGMA ADVISERS, LP (1.43Mn).